



**PB 56 of 2024**

# **National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (June Update) Instrument 2024**

*National Health Act 1953*

---

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the *National Health Act 1953*.

Dated 30 May 2024

**NIKOLAI TSYGANOV**  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division

---

---

# Contents

1	Name.....	1
2	Commencement.....	1
3	Authority .....	1
4	Schedules.....	1
<b>Schedule 1—Amendments</b>		<b>2</b>
	<i>National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)</i>	2

---

## 1 Name

- (1) This instrument is the *National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (June Update) Instrument 2024*
- (2) This instrument may also be cited as PB 56 of 2024.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

---

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. <i>The whole of this instrument</i>	<i>1 June 2024</i>	<i>1 June 2024</i>

---

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 100(2) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments

### ***National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)***

- [1] Schedule 1, Part 1, entry for Bortezomib in the form Powder for injection 1 mg

*omit:*

	Velcade	C11099 C13745
--	---------	---------------

- [2] Schedule 1, Part 1, entry for Bortezomib in the form Powder for injection 3 mg

*omit:*

	Velcade	C11099 C13745
--	---------	---------------

- [3] Schedule 1, Part 1, entry for Bortezomib in the form Powder for injection 3.5 mg

(a) *insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:*

	BORTEZOMIB EUGIA	C11099 C13745
--	------------------	---------------

(b) *omit:*

	Velcade	C11099 C13745
--	---------	---------------

- [4] Schedule 1, Part 1, entry for Nivolumab in each of the forms: Injection concentrate for I.V. infusion 40 mg in 4 mL; and Injection concentrate for I.V. infusion 100 mg in 10 mL

*omit from the column headed “Circumstances”:* C13852 C13863

- [5] Schedule 1, Part 1, entry for Pembrolizumab

*omit from the column headed “Circumstances”:* C13986

- [6] Schedule 1, Part 2, entry for Nivolumab [*Maximum Amount: 120 mg; Number of Repeats: 3*]

*omit from the column headed “Purposes”:* P13852

- [7] Schedule 1, Part 2, entry for Nivolumab [*Maximum Amount: 480 mg; Number of Repeats: 11*]

*omit from the column headed “Purposes”:* P13863

---

**[8] Schedule 1, Part 2, entry for Pembrolizumab [Maximum Amount: 400 mg; Number of Repeats: 6]**

*omit from the column headed "Purposes": P13986*

**[9] Schedule 2, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)**

*insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Ondansetron Tablets Viartis	C5778	4	0	V5778
--------------------------------	-------	---	---	-------

**[10] Schedule 2, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg**

*insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Ondansetron ODT Viartis	C5743	4	0	V5743
----------------------------	-------	---	---	-------

**[11] Schedule 2, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)**

*insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Ondansetron Tablets Viartis	C5778	4	0	V5778
--------------------------------	-------	---	---	-------

**[12] Schedule 3, Part 1, omit entry for Circumstances Code "C13852"**

**[13] Schedule 3, Part 1, omit entry for Circumstances Code "C13863"**

**[14] Schedule 3, Part 1, omit entry for Circumstances Code "C13986"**